Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases

Hypertension Research

Volumn 27, Issue 6, 2004, Pages 379-385

  Kojima, Shunichi ^a   Shida, Mikio ^a   Yokoyama, Hiroyuki ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Calcium channel blocker; N type calcium channel; Proteinuria; Renal function

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA 2 MICROGLOBULIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CREATININE; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN MESYLATE; EFONIDIPINE; ENALAPRIL MALEATE; IMIDAPRIL; LOSARTAN POTASSIUM; MANIDIPINE; NIFEDIPINE; TRANDOLAPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MALE; OUTPATIENT; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; CREATININE; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION, RENAL; LOGISTIC MODELS; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 3242891578     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.379     Document Type: Article

References (31)

1. Ruggenenti P, Perna A, Ghaerardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
2. Wright JT Jr, Bakris G, Greene T, et al: African American Study of Kidney Disease and Hypertension Study Group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
3. Brenner BM, Cooper ME, deZeeuw D, et al, for the RENAAL study investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: the effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al: Collaborative Study Group: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes. N Engl J Med 2001; 345: 851-860.
6. Makino H, NakamuraY, Wada J: Remission and regression of diabetic nephropathy. Hypertens Res 2003; 26: 515-519.
7. Bakris GL, Williams M, Dworkin L, et al, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000; 36: 646-661.
8. Ertel, EA, Campbell KP, Harpold MM: Nomenclature of voltage-gated calcium channels. Neuron 2000; 25: 533-535.
9. 2+ channels. Annu Rev Cell Dev Biol 2000; 16: 521-555.
10. Saruta T, Kanno Y, Hayashi K, Konishi K: Antihypertensive agents and renal protection: calcium channel blockers. Kidney Int 1996; 55 (Suppl): S52-S56.
11. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641-1650.
12. Hayashi K, Kumagai H, Saruta T: Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116-122.
13. 2+ channels distributed in cardiovascular system. Int J Mol Med 1999; 3: 455-466 (Review).
14. 2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblasatoma cells. Hypertens Res 2003; 26: 743-747.
15. Zhou X, Ono H, Ono Y, Frohlich ED: N- and L- type calcium channel antagonist improves glomerular dynamics, reserves severe nephrosclerosis, and inhibits apoptosis and proliferation in an L-NAME/SHR model. J Hypertens 2002; 20: 993-1000.
16. Rose GW, Kanno Y, Ikebukuro H, et al: Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24: 377-383.
17. Barajas L, Powers K, Wang P: Innervation of the renal cortical tubule: a quantitative study. Am J Physiol 1984; 247: F50-1760.
18. Barajas L, Powers K: Monoaminergic innervation of the rat kidney: a quantitative study. Am J Physiol 1990; 259: F503-F511.
19. Takahara A, Dohmoto H, Hisa H, Satoh S, Yamamoto R: Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Jpn J Pharmacol 1997; 75: 27-32.
20. Navar LG, Inscho EW, Imig JD, Mitchell KD: Heterogeneous activation mechanisms in the renal microvasculature. Kidney Int 1998; 67 (Suppl): s17-s21.
21. Fujii S, Okazaki Y, Yatabe Y, Hosono M, Kimura K: Potent vasodilative action of cilnidipine on glomerular arterioles in rat hydronephrotic kidney. Jpn Pharmacol Ther 1999; 27: 163-168.
22. Takeda S, Ueshiba H, Hattori Y, Irie M: Cilnidipine, the N-and L-type calcium channel antagonist, reduced on urinary 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1999; 44: 197-205.
23. Minami J, Ishimitsu T, Higashi T, Numabe A, Matsuoka H: Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Hypertens Res 1998; 21: 215-219.
24. Tomiyama H, Kimura Y, Kuwabara Y, et al: Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. Hypertens Res 2001; 24: 679-684.
25. Morimoto S, Takeda K, Oguni A, et al: Reduction of white coat effect by cilnidipine in essential hypertension. Am J Hypertens 2001; 14: 1053-1057.
26. Fukuhara T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Call channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997; 280: 1184-1191.
27. 2+ channels. Eur J Pharmacol 1999; 373: 93-100.
28. Ligtenberg G, Blankestijin PJ, Oey PL, et al: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328.
29. Sakata K, Shirotani M, Yoshida H, et al: Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33: 1447-1452.
30. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/Ca antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1280-1283.
31. Shigihara T, Sato A, Hayashi K, Saruta T: Effect of combination therapy of angiotensin-converting-enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res 2000; 23: 219-226.